Research programme: anti-cancer therapeutics - Aurigene/Curis

Drug Profile

Research programme: anti-cancer therapeutics - Aurigene/Curis

Alternative Names: AUPM-170; AUPM-327; CA 327; PD-L1 antagonists - Aurigene/Curis; PD-L1/TIM-3 antagonists - Aurigene/Curis; PD-L1/VISTA antagonists - Aurigene/Curis; Programmed death ligand-1 antagonists - Aurigene/Curis

Latest Information Update: 13 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aurigene Discovery Technologies
  • Class Antineoplastics; Small molecules
  • Mechanism of Action HAVCR2 protein inhibitors; Programmed cell death-1 ligand-1inhibitors; VISTA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Nov 2017 Curis announces intention to submit IND application of CA 327 to the US FDA in first half of 2018
  • 11 Oct 2016 Curis exercises its option to exclusively license small molecule antagonists of programmed death ligand-1 (PD-L1) and T-cell immunoglobulin and mucin domain containing protein-3 (CA 327)
  • 11 Oct 2016 Aurigene announces intention to submit IND for CA 327 in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top